Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID‐19
暂无分享,去创建一个
C. Poreaux | M. Kemula | C. Taieb | Z. Reguiai | E. Bégon | G. Chaby | A. Fougerousse | P. Bécherel | F. Maccari | V. Pallure | J. Parier | M. Perrussel | I. Zaraa | L. MÉRY-BOSSARD
[1] G. Pellacani,et al. Evolution of COVID‐19 infection in four psoriatic patients treated with biological drugs , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.
[2] V. Marmol,et al. Improvement of SARS‐CoV‐2 symptoms following Guselkumab injection in a psoriatic patient , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.
[3] R. Balestri,et al. SARS‐CoV‐2 infection in a psoriatic patient treated with IL‐17 inhibitor , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.
[4] N. Bragazzi,et al. Biologics increase the risk of SARS‐CoV‐2 infection and hospitalization, but not ICU admission and death: Real‐life data from a large cohort during red‐zone declaration , 2020, Dermatologic therapy.
[5] L. Naldi,et al. The impact of the COVID‐19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience , 2020, The British journal of dermatology.
[6] M. Rybojad,et al. Vascular skin symptoms in COVID‐19: a French observational study , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.
[7] David Berlin,et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases , 2020, Translational Research.
[8] M. Lebwohl,et al. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). , 2015, JAMA dermatology.
[9] F. Drago,et al. Atypical presentations of bullous pemphigoid: Clinical and immunopathological aspects. , 2015, Autoimmunity reviews.